Glen has made over 2 trades of the PRA Health Sciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 3,449 units of PRAH stock worth $279,369 on 11 January 2018.
The largest trade he's ever made was selling 3,449 units of PRA Health Sciences Inc stock on 11 January 2018 worth over $279,369. On average, Glen trades about 575 units every 1 days since 2017. As of 11 January 2018 he still owns at least 33,715 units of PRA Health Sciences Inc stock.
You can see the complete history of Glen Stettin stock trades at the bottom of the page.
Dr. Glen D. Stettin M.D. serves as Independent Director of the Company. Dr. Stettin is Senior Vice President and Chief Innovation Officer at Express Scripts & Cigna Services, a division of Cigna Corporation, where he heads up research and development, patient and physician experience, product development and management focused on new clinical solutions and data, analysis and platforms as services. Prior to that, Dr. Stettin served as Senior Vice President and Chief Innovation Officer of Express Scripts, which was acquired by Cigna Corporation in 2018. Dr. Stettin joined Express Scripts when the company merged with Medco Health Solutions, Inc. in April 2012. During his 17 years at Medco, he served in leadership roles in the clinical, operations, technology and product organizations. Dr. Stettin earned his bachelor and medical degrees through Lehigh University and the Medical College of Pennsylvania. He completed his residency in internal medicine at the University of California, San Francisco, where he also served as Medical Chief Resident at Moffitt-Long Hospital, Fellow in cardiology and Robert Wood Johnson Foundation Clinical Scholar at UCSF and Stanford University.
Glen Stettin is 55, he's been the Independent Director of PRA Health Sciences Inc since 2020. There are 5 older and 5 younger executives at PRA Health Sciences Inc. The oldest executive at PRA Health Sciences Inc is Jeffrey Barber, 67, who is the Independent Director.
Glen's mailing address filed with the SEC is 1 Express Way, St. Louis, MO 63121, USA.
Over the last 10 years, insiders at PRA Health Sciences Inc have traded over $5,843,308,181 worth of PRA Health Sciences Inc stock. The most active insiders traders include Fund Holdings L.P.Kkr Fund ..., Fund Holdings L.P.Kkr Fund ... et Pra Investors L.P.Kkr Pra I.... On average, PRA Health Sciences Inc executives and independent directors trade stock every 39 days with the average trade being worth of $280,602,577. The most recent stock trade was executed by Christopher L Gaenzle on 17 June 2021, trading 27,497 units of PRAH stock currently worth $2,773,897.
PRA is one of the world's leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 18,100 employees worldwide. Since 2000, PRA has participated in approximately 4,200 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 100 drugs.
PRA Health Sciences Inc executives and other stock owners filed with the SEC include: